Head-to-head comparison
| Property | CJC-1295 | Sermorelin |
|---|---|---|
| Category | Muscle & Growth | Muscle & Growth |
| Legal Status | Reclassification Pending | Reclassification Pending |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~30 minutes (no DAC) / ~8 days (with DAC) | ~10-20 minutes |
| Mol. Weight | 3,367.97 Da | 3,357.88 Da |
| Side Effects | Flushing, Headache, Dizziness | Injection site reactions, Facial flushing, Headache |
Key differences
- Half-life: CJC-1295 with DAC has a half-life of 6–8 days due to its Drug Affinity Complex; sermorelin has a half-life of only 10–20 minutes.
- Dosing frequency: CJC-1295 (with DAC) is typically dosed 1–2 times per week; sermorelin requires daily injections, usually before bedtime.
- GH release pattern: CJC-1295 produces sustained, elevated baseline GH levels; sermorelin produces acute, pulsatile GH release that decays quickly.
- Variants: CJC-1295 comes in two forms—with DAC (long-acting) and without DAC (Mod GRF 1-29, short-acting); sermorelin has no long-acting variant.
- FDA history: Sermorelin was previously FDA-approved (Geref); CJC-1295 has never been FDA-approved and remains a research compound.
- Common pairings: CJC-1295 (without DAC) is frequently paired with ipamorelin; sermorelin is used alone or with GHRP-2/GHRP-6.
- Physiological profile: Sermorelin more closely mimics natural GHRH pulsatility; CJC-1295 with DAC provides continuous stimulation that some researchers view as less physiological.
The verdict
The better choice depends on protocol goals. CJC-1295 (particularly the DAC variant) offers significantly greater dosing convenience with 1–2 weekly injections versus daily for sermorelin. Sermorelin provides a more physiological GH release pattern and has the advantage of prior FDA approval. For those who prefer a natural pulsatile pattern, sermorelin or CJC-1295 without DAC may be preferred; for convenience and sustained elevation, CJC-1295 with DAC is the common choice.
Frequently asked questions
Both are GHRH analogs that stimulate growth hormone release, but CJC-1295 (with DAC) has a half-life of 6–8 days compared to sermorelin's 10–20 minutes. This means CJC-1295 requires far fewer injections but produces sustained rather than pulsatile GH elevation.
CJC-1295 with DAC (Drug Affinity Complex) has a dramatically extended half-life of 6–8 days, enabling weekly dosing. CJC-1295 without DAC is essentially Mod GRF 1-29, with a half-life of about 30 minutes, requiring more frequent administration similar to sermorelin.
Both act on the same GHRH receptor, so combining them would be redundant. Researchers typically choose one GHRH analog and may pair it with a ghrelin-pathway peptide like ipamorelin or GHRP-6 for synergistic GH release.
Both aim to restore youthful GH levels. Sermorelin is often preferred in anti-aging protocols for its more physiological pulsatile pattern. CJC-1295 with DAC is preferred when dosing convenience is a priority. Clinical evidence for anti-aging benefits remains limited for both.
Sermorelin has a more established safety profile, including prior FDA approval history. CJC-1295 has not been FDA-approved and has fewer published safety studies. Both are generally considered well-tolerated in preclinical and off-label use, but long-term safety data is limited for both.